z-logo
open-access-imgOpen Access
A Novel Live-Attenuated Vaccine Candidate for Mayaro Fever
Author(s) -
W. Weise,
Meghan E. Hermance,
Naomi L. Forrester,
Alexandra Adams,
Rose M. Langsjoen,
Rodion Gorchakov,
Eryu Wang,
Maria D. H. Alcorn,
Konstantin A. Tsetsarkin,
Scott C. Weaver
Publication year - 2014
Publication title -
plos neglected tropical diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.99
H-Index - 135
eISSN - 1935-2735
pISSN - 1935-2727
DOI - 10.1371/journal.pntd.0002969
Subject(s) - virology , attenuated vaccine , yellow fever , dengue fever , alphavirus , biology , vaccination , dengue virus , virus , immunology , dengue vaccine , medicine , virulence , genetics , gene
Mayaro virus (MAYV) is an emerging, mosquito-borne alphavirus that causes a dengue-like illness in many regions of South America, and which has the potential to urbanize. Because no specific treatment or vaccine is available for MAYV infection, we capitalized on an IRES-based approach to develop a live-attenuated MAYV vaccine candidate. Testing in infant, immunocompetent as well as interferon receptor-deficient mice demonstrated a high degree of attenuation, strong induction of neutralizing antibodies, and efficacy against lethal challenge. This vaccine strain was also unable to infect mosquito cells, a major safety feature for a live vaccine derived from a mosquito-borne virus. Further preclinical development of this vaccine candidate is warranted to protect against this important emerging disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom